Kymera COO exercises options, sells 25,758 shares

Kymera Therapeutics, Inc. Chief Operating Officer Jeremy G. Chadwick exercised stock options for 20,000 shares of common stock at an exercise price of $43.50 per share.

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. Chief Operating Officer Jeremy G. Chadwick exercised stock options for 20,000 shares of common stock at an exercise price of $43.50 per share. He then sold a total of 25,758 shares of common stock in open-market transactions at weighted average prices of $82.1275, $83.1013, and $83.7195 per share, as part of multiple trades within specified price ranges.

The filing states these transactions were completed under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025. Following the transactions, Chadwick directly holds 68,052 shares of Kymera Therapeutics common stock.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Chadwick Jeremy G

Role Chief Operating Officer

Sold 25,758 shs ($2.15M)

Approx. gross sale proceeds $2.15M

Approx. exercise cost $870K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	20,000	$0.00	$0.00
Exercise	Common Stock	20,000	$43.50	$870K
Sale	Common Stock	1,765	$82.1275	$145K
Sale	Common Stock	12,882	$83.1013	$1.07M
Sale	Common Stock	11,111	$83.7195	$930K

Holdings After Transaction: Stock Option (Right to Buy) — 60,548 contracts (Direct); Common Stock — 68,052 shares (Direct)

Footnotes (5)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.47 to $82.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.47 to $83.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.47 to $84.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Kymera Therapeutics (KYMR) report for its COO?

Kymera’s COO Jeremy G. Chadwick exercised options for 20,000 shares and sold 25,758 shares. The sales occurred in open-market trades at weighted average prices around $82–$84 per share, and he retained 68,052 shares directly afterward.

At what price did the Kymera Therapeutics (KYMR) COO exercise his stock options?

Jeremy G. Chadwick exercised stock options at an exercise price of $43.50 per share. This converted 20,000 option rights into 20,000 shares of Kymera common stock before subsequent open-market sales reported in the same Form 4 filing.

How many Kymera Therapeutics (KYMR) shares did the COO sell and at what prices?

The COO sold 25,758 shares of Kymera common stock in open-market transactions. Weighted average sale prices were $82.1275, $83.1013, and $83.7195 per share, each representing multiple trades within specific price ranges disclosed in the footnotes.

How many Kymera Therapeutics (KYMR) shares does the COO hold after these transactions?

After completing the option exercise and share sales, Jeremy G. Chadwick holds 68,052 shares directly. This figure reflects his remaining Kymera common stock position as shown in the post-transaction ownership columns of the Form 4.

Were the Kymera Therapeutics (KYMR) COO’s share sales under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan. The plan was dated December 10, 2025, indicating the sales were pre-arranged rather than decided at the time of trading.

What does the vesting footnote say about the Kymera (KYMR) COO’s stock options?

The stock option underlying these 20,000 exercised shares vests in 36 equal monthly installments. Vesting begins after March 1, 2024, subject to Chadwick’s continued employment through each monthly vesting date, according to the footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/11/2026 - 06:51 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chadwick Jeremy G

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		M(1)		20,000	A	$43.5	93,810	D
Common Stock	03/11/2026		S(1)		1,765	D	$82.1275(2)	92,045	D
Common Stock	03/11/2026		S(1)		12,882	D	$83.1013(3)	79,163	D
Common Stock	03/11/2026		S(1)		11,111	D	$83.7195(4)	68,052	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$43.5	03/11/2026		M(1)			20,000	(5)	02/28/2034	Common Stock	20,000	$0	60,548	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.47 to $82.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.47 to $83.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.47 to $84.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date.

	/s/ Bruce Jacobs, as Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.